Market Analysis
Novo Nordisk Shares Rise After FDA Pressures Hims to Pull Weight-Loss Pill
Novo Nordisk stock jumped 8% after Hims & Hers withdrew its knockoff Wegovy pill amid FDA scrutiny and legal threats.
BTC$63,908.00+0.13%
ETH$1,840.65-1.26%
USDT$0.9993+0.01%
USDC$0.9999+0.00%
XRP$1.09+0.23%
SOL$74.98-0.31%
TRX$0.3226-0.09%
FIGR_HELOC$1.03+2.52%
HYPE$59.69-1.66%
DOGE$0.0725+0.33%
USDS$0.99980.00%
RAIN$0.0141-2.92%
ZEC$545.93+3.85%
LEO$9.80+0.03%
WBT$55.74-0.08%
BTC$63,908.00+0.13%
ETH$1,840.65-1.26%
USDT$0.9993+0.01%
USDC$0.9999+0.00%
XRP$1.09+0.23%
SOL$74.98-0.31%
TRX$0.3226-0.09%
FIGR_HELOC$1.03+2.52%
HYPE$59.69-1.66%
DOGE$0.0725+0.33%
USDS$0.99980.00%
RAIN$0.0141-2.92%
ZEC$545.93+3.85%
LEO$9.80+0.03%
WBT$55.74-0.08%
Hims & Hers stock jumped more than 7% in premarket trading after the company agreed to acquire digital health platform Eucalyptus in a deal worth up to $1.15 billion.
Novo Nordisk stock jumped 8% after Hims & Hers withdrew its knockoff Wegovy pill amid FDA scrutiny and legal threats.
Hims & Hers stock rose over 10% after the company unveiled plans to sell a cheaper compounded version of Novo Nordisk’s Wegovy pill.
Novo Nordisk ended its month-old partnership with Hims & Hers Health over illegal drug compounding practices.